BCMA/CD47-directed UCAR-T cells demonstrated efficacy against MM and prolonged the survival of tumor-engrafted NCG mice in vivo, which provides a potential strategy for the development of a novel “off-the-shelf” cellular immunotherapies for the treatment of multiple myeloma. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.